糖尿病视网膜病变严重程度评分变化的临床重要性
本文为RIDE与RISE两项III期研究的post hoc分析,纳入468只接受雷珠单抗(ranibizumab)治疗并有可分级基线眼底照片的糖尿病黄斑水肿(DME)眼,按基线至第24个月糖尿病视网膜病变严重程度评分(DRSS)变化分组比较视功能与解剖结局。结果显示DRSS稳定或改善者平均最佳矫正视力(BCVA)字母评分变化更大,黄斑水肿消退更常见;作者认为DRSS改善是应作为疗效指标评估的临床重要结局。
要点
- 接受雷珠单抗治疗的眼56.8%在24个月时DRSS改善≥1级,40.0%无变化,3.2%恶化。
- DRSS改善≥3级、≥2级、1级及无变化者平均BCVA分别变化+15.1、+14.2、+11.3、+11.2个字母,任何DRSS恶化者为+5.0个字母。
- DRSS改善≥3级、≥2级者BCVA增益≥15个字母的比例分别为44.6%和51.9%,高于1级改善、无变化及恶化者的37.9%、39.6%和26.7%。
核心结论
- DRSS改善是临床重要结局,未来糖尿病眼病研究应将其作为治疗有效性指标评估。
研究设计与样本
- RIDE与RISE两项III期研究的post hoc分析,纳入468只接受雷珠单抗治疗且基线眼底照片DRSS可分级眼。
主要发现
- 56.8%接受雷珠单抗治疗眼基线至第24个月DRSS改善≥1级,40.0%无变化,3.2%恶化。
- DRSS改善≥3级、≥2级、1级及无变化者平均BCVA字母评分分别变化+15.1、+14.2、+11.3、+11.2个字母,任何DRSS恶化者为+5.0个字母。
- BCVA增益≥15个字母在DRSS改善≥2级和≥3级者分别为51.9%和44.6%,1级改善、无变化和恶化者分别为37.9%、39.6%和26.7%。
- BCVA丧失≥15个字母在DRSS恶化者为13.3%,DRSS稳定或改善者为0%-2.8%。
- DRSS改善1级、≥2级、≥3级者黄斑水肿消退(中心凹厚度≤250 μm)分别为84.2%、87.7%、92.3%,无变化者和恶化者分别为65.2%和53.3%。
关键数值与推荐
- DRSS改善≥3级、≥2级、1级及无变化者平均BCVA字母评分变化分别为+15.1、+14.2、+11.3、+11.2个字母,任何DRSS恶化者为+5.0个字母。
- DRSS改善≥2级和≥3级者BCVA增益≥15个字母比例分别为51.9%和44.6%。
- DRSS改善1级、≥2级、≥3级者中心凹厚度≤250 μm比例分别为84.2%、87.7%、92.3%,无变化者和恶化者分别为65.2%和53.3%。
临床怎么用
- 作者认为DRSS改善是临床重要结局,未来糖尿病眼病研究应将其作为治疗有效性指标评估。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To investigate the clinical importance of changes in diabetic retinopathy severity score (DRSS) in patients with diabetic macular edema (DME) treated with intravitreal ranibizumab. DESIGN: Post hoc analysis of the phase III RIDE and RISE studies of ranibizumab for treatment of DME. PARTICIPANTS: Four hundred sixty-eight eyes treated with ranibizumab from randomization with gradable DRSS on baseline fundus photographs. METHODS: Visual and anatomic outcomes were examined in eyes grouped according to DRSS change from baseline to month 24. MAIN OUTCOME MEASURES: Mean best-corrected visual acuity (BCVA) letter score change, proportion of patients with 15 or more Early Treatment Diabetic Retinopathy Study (ETDRS) letter score change, mean contrast sensitivity change, proportion of patients with resolved macular edema, and leakage on fluorescein angiography. RESULTS: Most (56.8%) patients treated with ranibizumab experienced 1-step or more improvement in DRSS from baseline to month 24; 40.0% had no change, and 3.2% experienced DRSS worsening. Patients with DRSS stability or improvement had greater mean BCVA letter score changes (+15.1, +14.2, +11.3, and +11.2 letters for ≥3-step improvement, ≥2-step improvement, 1-step improvement, and no DRSS change, respectively) compared with +5.0 letters in patients who had any DRSS worsening. Best-corrected visual acuity letter score gain of 15 letters or more was more common in patients with 2-step or 3-step or more DRSS improvement (51.9% and 44.6%, respectively) compared with those with a 1-step DRSS improvement, no change, or worsening (37.9%, 39.6%, and 26.7%, respectively). A loss of 15 letters or more in BCVA was more common in patients with any DRSS worsening (13.3%) compared with patients who had stable or improved DRSS (0%-2.8%). Resolution of macular edema was more common in patients with DRSS improvement: 84.2%, 87.7%, and 92.3% of patients with 1-step, 2-step or more, and 3-step or more improvement in DRSS achieved central foveal thickness of 250 μm or less, compared with 65.2% and 53.3% of patients who had no DRSS change or any DRSS worsening. CONCLUSIONS: These findings provide further support that improvement in DRSS is a clinically important outcome that should be evaluated as a measure of treatment effectiveness in future studies of diabetic eye disease.
引用
- Ip MS, Zhang J, Ehrlich JS, et al. The Clinical Importance of Changes in Diabetic Retinopathy Severity Score. Ophthalmology. 2017. PMID: 28284785. doi:10.1016/j.ophtha.2017.01.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。